Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 064: Sequential Nivolumab and Ipilimumab in Melanoma
NCT01783938Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2013
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants With Treatment-Related Grade 3-5 Adverse Events at Week 25. Started Apr 2013; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01783938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01783938.